Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001062993-23-016508
Filing Date
2023-08-15
Accepted
2023-08-15 16:05:52
Documents
2
Period of Report
2023-08-08

Document Format Files

Seq Description Document Type Size
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.html 3  
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.xml 3 9206
2 POA exhibit24-1.txt EX-24.1 2850
  Complete submission text file 0001062993-23-016508.txt   13612
Mailing Address 80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333
Business Address 80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333 484-581-7505
Zynerba Pharmaceuticals, Inc. (Issuer) CIK: 0001621443 (see all company filings)

EIN.: 260389433 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZYNERBA PHARMACEUITCALS, INC. 80 W. LANCASTER AVENUE, SUITE 300 DEVON PA 19333
Business Address
Jones Kenneth T (Reporting) CIK: 0001988882 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37526 | Film No.: 231174891